IDEXX Laboratories Reports Strong Q1 2026 Results, Boosts Annual Outlook

IDEXX Laboratories Reports Strong Q1 2026 Results, Boosts Annual Outlook

Tue, July 07, 2026

IDEXX Laboratories Reports Strong Q1 2026 Results, Boosts Annual Outlook

WESTBROOK, Maine—IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced robust financial results for the first quarter of 2026, showcasing significant growth across its business segments and an optimistic outlook for the remainder of the year.

First Quarter Financial Highlights

For the quarter ending March 31, 2026, IDEXX reported revenues of $1.141 billion, marking a 14% increase as reported and an 11% rise on an organic basis compared to the same period in the previous year. This growth was primarily driven by the Companion Animal Group (CAG), which saw a 15% increase as reported and 12% organically.

Earnings per diluted share (EPS) reached $3.47, reflecting a 17% increase as reported and a 15% rise on a comparable basis. The company’s operating margin expanded by 10 basis points as reported and 100 basis points on a comparable basis, underscoring improved operational efficiency.

Companion Animal Group Performance

The CAG segment’s strong performance was highlighted by:

  • IDEXX VetLab™ Consumables: Achieved 20% revenue growth as reported and 15% organically, supported by increased testing utilization, recent product launches, and a 12% growth in the global premium instrument installed base.
  • Reference Laboratory Diagnostic and Consulting Services: Recorded 12% revenue growth as reported and 10% organically, benefiting from higher testing volumes and net new customer gains.
  • Rapid Assay Products: Experienced a 1% increase in revenues as reported, with volumes impacted by the adoption of the Catalyst™ Pancreatic Lipase Test, which shifted some testing across modalities.

Additionally, CAG Diagnostics capital instrument revenues expanded by 33% as reported and 28% on an organic basis, driven by strong instrument placements, including 1,100 IDEXX inVue Dx™ units.

Innovation and Product Adoption

CEO Jay Mazelsky highlighted the company’s innovation-driven growth strategy, noting the momentum of the IDEXX Cancer Dx™ platform, which has seen growing adoption in the U.S. and a recent international launch. The controlled rollout of IDEXX inVue Dx™ FNA has also received positive initial customer feedback, supporting plans for broader access throughout the year.

Updated 2026 Financial Guidance

Reflecting the strong first-quarter performance, IDEXX raised its 2026 revenue guidance to a range of $4.675 billion to $4.760 billion, up approximately 1% at the midpoint. The company now projects reported revenue growth of 8.6% to 10.6% and CAG Diagnostics recurring revenue growth of 9.6% to 11.6%, with projected organic revenue growth of 7.7% to 9.7% and CAG Diagnostics recurring revenue organic growth of 8.7% to 10.7%.

Market Performance

As of July 6, 2026, IDEXX Laboratories’ stock (NASDAQ: IDXX) closed at $564.98, reflecting a 0.64% increase from the previous close. The stock’s performance aligns with the company’s strong financial results and positive outlook.

Conclusion

IDEXX Laboratories’ impressive first-quarter results and upward revision of its annual guidance underscore the company’s robust growth trajectory and commitment to innovation in the veterinary diagnostics and animal health sectors. Investors and stakeholders can anticipate continued strong performance as IDEXX leverages its expanding product portfolio and global market presence.